Sort
48,018 grants matching “immunotherapy”
Cytokines in AIDS and Cancer Immunotherapy
$989,274George N. Pavlakis · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
PEDIATRIC AIDS CLINICAL TRIAL UNIT
$989,191Univ Of Massachusetts Med Sch Worcester · U01 · FY2002 · AI
Multi-Omic Single-Cell System for Improved Combination Cancer Immunotherapy Monitoring and Implementation
$988,980Timothy S McConnell · Isoplexis, Inc. · R44 · FY2020 · CA
Novel immunotherapy against MOG antibody disease
$988,943Weston Daniel · Evoq Therapeutics, Inc. · R44 · FY2025 · TR
Molecular, Cellular, and Tissue Characterization Unit
$988,750William E Gillanders · Washington University · U2C · FY2021 · CA
Clinical Protocol and Data Management
$988,548Jeffrey A Meyerhardt · Dana-Farber Cancer Inst · P30 · FY2022 · CA
Clinical Protocol and Data Management
$988,546Jeffrey A Meyerhardt · Dana-Farber Cancer Inst · P30 · FY2023 · CA
A Serological Assay for Neutralizing Antitoxin Response in Patients with Clostridioides difficile Infection (Phase II)
$988,488Zhiyong Yang · Fzata, Inc. · R44 · FY2022 · AI
Phase 1/2 Clinical Study of Humanized Anti-BCMA CAR T Cells in Relapsed/Refractory Multiple Myeloma (MM)
$988,226Charles Andrew Stewart · Cartesian Therapeutics, Inc. · R44 · FY2021 · CA
Phase 1/2 Clinical Study of Humanized Anti-BCMA CAR T Cells in Relapsed/Refractory Multiple Myeloma (MM)
$988,226Charles Andrew Stewart · Cartesian Therapeutics, Inc. · R44 · FY2020 · CA
Immunomodulatory biomaterial to enhancing T-cell responses to triple negative breast cancer
$987,911Dashtimoghadam Erfan · Symphony Biosciences, Inc. · R44 · FY2025 · CA
Humanized monoclonal antibodies to treat mucormycosis
$987,901Gary Lazar · Vitalex Biosciences, Llc · R44 · FY2023 · AI
Programming T Cell Fates for Therapeutic Use
$987,437Luca Gattinoni · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
Clinical Studies for Improving Survival Rates for Oral Cancer Patients in Low Resource Settings
$987,292Manijeh N Goldberg · Privo Technologies, Llc · R44 · FY2023 · CA
A Novel Immunological-Directed Biotherapy for Treating Rheumatoid Arthritis
$987,225Gary Fanger · Rise Therapeutics, Llc · R44 · FY2024 · AG
Understanding the immune response changes to clinical interventions for Epstein-Barr virus infection prior to lymphoma development in children after organ transplants (UNEARTH)
$987,185Vikas R. Dharnidharka · Washington University · U01 · FY2023 · CA
Developing novel targeted therapeutics integrated with immunotherapy-based approaches to make breakthroughs in metastatic breast cancer
$987,088Jean Zhao · Dana-Farber Cancer Inst · R35 · FY2022 · CA
Coordinating and Data Management Center for Acquired Resistance to Therapy Network
$986,818Alan David Hutson · Roswell Park Cancer Institute Corp · U24 · FY2024 · CA
A human cytomegalovirus-based immunotherapy for HIV-1
$986,519Eric Bruening · Tomegavax, Inc. · R44 · FY2015 · AI
Molecular mechanisms of antibody-mediated immunotherapies
$986,490Jeffrey Victor Ravetch · Rockefeller University · R35 · FY2019 · CA
Targeting Epigenetic Circuits in B-Cell Lymphomas
$986,490Ari M. Melnick · Weill Medical Coll Of Cornell Univ · R35 · FY2019 · CA
Preclinical GEM and GDA Models of Primary and Metastatic Melanoma
$986,350Shyam Sharan · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Prophylactic Immunotherapy for Marburg Virus Disease Outbreak Control
$986,248M. Javad Aman · Abvacc, Inc. · R44 · FY2023 · AI
A human cytomegalovirus-based immunotherapy for HIV-1
$986,188Eric Bruening · Tomegavax, Inc. · R44 · FY2016 · AI
Modeling the ecology of tissue-resident T cells
$986,013Andrew Yates · Columbia University Health Sciences · U01 · FY2020 · AI